Soleno Therapeutics Investor Relations Material
Latest events
AGM 2024
Soleno Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Soleno Therapeutics Inc
Access all reports
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare diseases. The company's primary focus is on Prader-Willi Syndrome (PWS), a genetic disorder characterized by chronic hunger, behavioral problems, and other severe health issues. Soleno's lead product candidate, Diazoxide Choline Extended-Release (DCCR) tablets, is currently undergoing evaluation in a Phase III clinical trial as a potential treatment for PWS. This once-daily oral medication aims to address the disorder's hallmark symptoms and improve patient outcomes. The company is headquartered in Redwood City, California, and its shares are listed on NASDAQ.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
SLNO
Country
🇺🇸 United States